Inozyme Pharma Q2 EPS $(0.35) Beats $(0.43) Estimate
Portfolio Pulse from Benzinga Newsdesk
Inozyme Pharma reported Q2 losses of $(0.35) per share, beating the analyst consensus estimate of $(0.43) by 18.6 percent. This represents a 7.89 percent increase over losses from the same period last year.
August 08, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inozyme Pharma's Q2 earnings beat analyst estimates by 18.6%, showing an improvement from last year's Q2.
Inozyme Pharma's Q2 earnings beat analyst estimates, which is generally seen as a positive sign by investors. This could lead to an increase in the company's stock price in the short term. The fact that the company's losses are decreasing compared to the same period last year also indicates a positive trend in the company's financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100